Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 2,761 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Activity Clear all

Conditions: Healthy
Interventions: exercise training; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Post Traumatic Stress Disorder, Problem Drinking
Interventions: App-based intervention; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: B Precursor Type Acute Leukemia
Interventions: Dietary Intervention, Activity and Exercise Intervention; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 10 Years to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections, Hypertriglyceridemia
Interventions: Fenofibrate, Fish Oil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 5
States / cities: San Francisco, California • Atlanta, Georgia • Cincinnati, Ohio + 2 more

Conditions: Depressive Symptoms
Interventions: DepCare, Enhanced Usual Care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV, AIDS, Obesity
Interventions: antiretroviral therapy; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cocaine Use Disorders
Interventions: Lorcaserin, 10 mg, Lorcaserin, 20 mg, Oral Placebo; Drug · Other
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 21 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Crohn's Disease
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 48
States / cities: Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more

Conditions: Blood Pressure
Interventions: Community Health Worker (CHW), Remote Blood Pressure (BP) Management Program (RBPM); Behavioral · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • Houston, Texas + 1 more

Conditions: Adolescent Well-Being, Mental Disorders, Severe
Interventions: Not listed
Lead sponsor: Outcome Referrals, Inc.; Industry
Eligibility: 12 Years to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Framingham, Massachusetts

Conditions: HIV Infections, Dyslipidemia, Endothelial Dysfunction
Interventions: extended release niacin; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution; Combination Product · Drug
Lead sponsor: PolyActiva Pty Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Exercise-induced Muscle Soreness, Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Cartilage Turnover
Interventions: NEM® brand eggshell membrane powder, curQ+® brand highly absorbable curcumin, EM Placebo, Curc Placebo, NEM® plus curQ+® combination; Dietary Supplement
Lead sponsor: ESM Technologies, LLC; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Acute Heart Failure
Interventions: Sodium nitroprusside, Dobutamine, Furosemide; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 12 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Pasadena, California • San Francisco, California • St Louis, Missouri + 1 more

Conditions: HIV Infections
Interventions: VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Bakersfield, California • DeLand, Florida • Newark, New Jersey

Conditions: Canavan Disease
Interventions: AAV9 BBP-812; Biological
Lead sponsor: Aspa Therapeutics; Industry
Eligibility: Up to 30 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 4
States / cities: Oakland, California • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Schizophrenia
Interventions: Neuroadaptive cognitive training, Computer games; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years to 35 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity, Physical Activity, Diabetes
Interventions: High Intensity Arm (Intervention), Low Intensity Arm (Comparison); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 556 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Fibrosis
Interventions: placebo, BIBF 1120; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Scottsdale, Arizona • San Francisco, California • Santa Barbara, California + 23 more

Conditions: Neoplasms
Interventions: Ziv-Aflibercept, Ganetespib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer Survivorship, Obesity, Overweight
Interventions: Group-based education and discussion, Individual 1:1 counseling, Group based behavioral skills development and cooking demonstrations, BfitBwell; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV
Interventions: Truvada, Combivir, Trizivir; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Circulatory Levels of Irisin in Response to Acute Resistance Training

Tools for Health and Resilience Implemented After Violence Exposure (Project THRIVE)

Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

Obesity in HIV After Antiretroviral Therapy

Lorcaserin Intra Venous Cocaine Effects

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

PRESSURE CHECK: Find Your Path to Better Health

Adolescents' Well-being in Community-based Treatment Versus Residential Treatment

Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

Effects of Eggshell Membrane and Curcumin Extract Supplementation, Separately or Combined, on Recovery From Intense Exercise

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)

Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis

Coalition for a Healthier Community-Utah Women and Girls - Phase II (UWAG-II)

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

BfedBwell Proof-of-Concept Pilot

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects